The Effects of Prenatal Pravastatin Treatment in the Rabbit Fetal Growth Restriction Model
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023698%3A_____%2F23%3AN0000044" target="_blank" >RIV/00023698:_____/23:N0000044 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/23:43926129
Result on the web
<a href="https://www.mdpi.com/2227-9059/11/10/2685" target="_blank" >https://www.mdpi.com/2227-9059/11/10/2685</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/biomedicines11102685" target="_blank" >10.3390/biomedicines11102685</a>
Alternative languages
Result language
angličtina
Original language name
The Effects of Prenatal Pravastatin Treatment in the Rabbit Fetal Growth Restriction Model
Original language description
Fetal growth restriction (FGR) remains without an effective prenatal treatment. Evidence from murine FGR models suggests a beneficial effect of prenatal pravastatin. Since the rabbit hemodichorial placenta more closely resembles the human condition, we investigated the effects of prenatal maternal pravastatin administration in the rabbit FGR model. At a gestational age of 25 days (term 31d), pregnant dams underwent partial uteroplacental vessel ligation (UPVL) in one uterine horn to induce FGR, leaving the other horn as a control. Dams were randomized to either receive 5 mg/kg/d pravastatin dissolved in their drinking water or normal drinking water until delivery. At GA 30d, the rabbits were delivered and were divided into four groups: control without pravastatin (C/NoPrav), FGR without pravastatin (FGR/NoPrav), FGR with pravastatin (FGR/Prav), and controls with pravastatin (C/Prav). The newborn rabbits underwent pulmonary functional assessment and neurobehavioral assessment, and they were harvested for alveolar morphometry or neuropathology. The placentas underwent histology examination and RNA expression. Birth weight was lower in the FGR groups (FGR/Prav, FGR/NoPrav), but there was no difference between FGR/Prav and C/NoPrav. No differences were noted in placental zone proportions, but eNOS in FGR/Prav placentas and VEGFR-2 in FGR/Prav and C/Prav were upregulated. There were no differences in pulmonary function assessment and alveolar morphometry. FGR/Prav kittens had increased neurosensory scores, but there were no differences in neuromotor tests, neuron density, apoptosis, and astrogliosis. In conclusion, in the rabbit FGR model, pravastatin upregulated the expression of VEGFR-2 and eNOS in FGR placentas and was associated with higher neurosensory scores, without measurable effects on birthweight, pulmonary function and morphology, and neuron density.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BIOMEDICINES
ISSN
2227-9059
e-ISSN
2227-9059
Volume of the periodical
11
Issue of the periodical within the volume
10
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
2685
UT code for WoS article
001092339100001
EID of the result in the Scopus database
2-s2.0-85175458582